WARSAW, Ind., Nov. 09, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System (“VerteGlide”), an innovative solution designed specifically for the treatment of Early Onset Scoliosis (“EOS”).
OrthoPediatrics Announces Full Commercial Launch of VerteGlide® Spinal Growth Guidance System Successful Limited Launch Highlights Strong Demand and Adoption of the Company’s Innovative Early Onset Scoliosis Solution
commercial launchearly onset scoliosis#orthopediatricsVerteGlide Spinal Growth Guidance System
VerteGlide further strengthens OrthoPediatrics' comprehensive scoliosis portfolio and reinforces the Company's commitment to developing pediatric-specific solutions for complex spinal deformities. It was developed to address a significant clinical challenge in treating children with EOS: achieving meaningful deformity correction while preserving the potential for continued spinal growth. Utilizing established spinal growth guidance principles, VerteGlide provides three-dimensional deformity correction while allowing natural growth to continue through additional vertebral segments, offering surgeons an additional growth-friendly treatment option for children with complex spinal deformities.
Dr. Josh Murphy, a pediatric orthopedic spine surgeon at Children's Healthcare of Atlanta, commented, “Treating Early Onset Scoliosis requires balancing meaningful deformity correction with the preservation of spinal growth potential. My experience with VerteGlide across multiple patients has been very encouraging, and I believe growth-guidance technology offers an important treatment option for appropriately selected children with these complex spinal deformities.”
“The full commercial launch of VerteGlide represents an important milestone for our scoliosis business and underscores the continued need for innovation in the treatment of Early Onset Scoliosis,” said Greg Odle, President of OrthoPediatrics Scoliosis. “Strong adoption across the U.S. reflects increasing interest among pediatric spine surgeons in growth-guidance technologies. We are excited about VerteGlide’s potential to expand treatment options for EOS patients with complex spinal pathologies. As we build on this momentum, we remain focused on expanding surgeon education and bringing this innovative technology to more children and families.”
The VerteGlide Spinal Growth Guidance System is made possible with the Shilla™ technology licensed from Medtronic.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 95 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
OrthoPediatrics announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System, targeting the Early Onset Scoliosis market. This move strengthens their scoliosis portfolio and leverages strong U.S. adoption, indicating significant market interest in growth-guidance technologies. The company's strategy includes expanding surgeon education to drive further market penetration and capitalize on this innovative solution, which utilizes licensed Medtronic Shilla™ technology.
- The full commercial launch strengthens OrthoPediatrics' scoliosis portfolio and addresses the Early Onset Scoliosis market.
- Strong U.S. adoption reflects increasing market interest in growth-guidance technologies, supported by licensed Medtronic Shilla™ technology.
PhD Lens: Clinical and outcomes impact
The VerteGlide® Spinal Growth Guidance System, now fully launched by OrthoPediatrics, offers a growth-friendly treatment for Early Onset Scoliosis. It employs established spinal growth guidance principles to achieve three-dimensional deformity correction while preserving spinal growth potential. Clinical experience from Dr. Josh Murphy indicates encouraging results across multiple patients, providing an important additional option for complex spinal deformities, utilizing licensed Shilla™ technology from Medtronic.
- VerteGlide provides three-dimensional deformity correction while preserving spinal growth potential, utilizing established growth guidance principles.
- Early clinical experience is encouraging, offering an additional growth-friendly treatment option for complex Early Onset Scoliosis.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.